INmune Bio (INMB)

• Market cap: $190M
• 1 day: -5.50%
• 5 days: -7.63%
• 1 month: 31.55%
• 3 months: 80.46%
• 6 months: 25.40%
• Year to date: 74.24%
• 1 year: -31.77%
• 5 years: 64.56%
• 10 years: 7.51%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Employees: 17

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

386% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 7

369% more call options, than puts

Call options by funds: $1.78M | Put options by funds: $379K

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

6% more funds holding

Funds holding: 66 [Q3] → 70 (+4) [Q4]

3.66% more ownership

Funds ownership: 24.17% [Q3] → 27.83% (+3.66%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% less capital invested

Capital invested by funds: $28.9M [Q3] → $28.8M (-$55.3K) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 168% upside
• Avg. target: $27 208% upside
• High target: $30 249% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 24% 1-year accuracy 8 / 33 met price target	249% upside $30	Buy Maintained	13 Feb 2025
Scotiabank George Farmer 29% 1-year accuracy 7 / 24 met price target	168% upside $23	Sector Outperform Maintained	11 Feb 2025